Search results
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
Zacks via Yahoo Finance· 2 days agoAccording to the company, TERN-701 has the potential to be a differentiated BCR-ABL inhibitor with...
What's Going On With Neurological Disease Focused Trevena On Thursday? - Trevena (NASDAQ:TRVN)
Benzinga· 1 day agoShares of Trevena Inc TRVN are trading lower on Thursday, with a session volume of 23.65 million, as...
Is Immunotherapy for Cat Allergy Effective?
Medscape· 4 days agoIn the field of allergology, desensitization to animals, specifically cats, is rarely prescribed. Has allergen immunotherapy (IT), which has long been...
Pharma giant's data breach exposes patients' sensitive information
Fox News· 4 days agoU.S. pharmaceutical giant Cencora has been affected by a data breach. The company is notifying...
Top Three Swiss Dividend Stocks For June 2024
Simply Wall St. via Yahoo Finance· 2 days agoThe Switzerland market displayed modest gains on Wednesday, navigating through a volatile trading session as investors awaited key policy decisions from...
Asthma Treatment During Pregnancy: Stay the Course!
Medscape· 2 days agoPregnancy is a period of asthma instability; it entails an increased risk for exacerbations. While therapeutic de-escalation, if not the outright...
What's the MACE Risk With Moderate to Severe Eczema?
Medscape· 3 days agoThe findings contrast with the expectation that increased systemic inflammation in moderate to severe AD would correspond with a higher incidence of...
McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug
Zacks· 2 days agoThe availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is...
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
Zacks· 3 days agoTerns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
InvestorPlace· 4 days agoWith biotech stocks enjoying a permanently relevant narrative, investors should focus on these...
